Melanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye
Molecular Pharmaceutics · 03.02.2025 · 22 (2) · 721-732
DOI: 10.1021/acs.molpharmaceut.4c00694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 09.01.2025. Verfasst von Annika Valtari und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Melanins, Glaucoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Business Finland.
Abstract (Originalsprache)
Glaucoma is a vision-threatening disease that is currently treated with intraocular-pressure-reducing eyedrops that are instilled once or multiple times daily. Unfortunately, the treatment is associated with low patient adherence and suboptimal treatment outcomes. We developed carbonic anhydrase II inhibitors (CAI-II) for a prolonged reduction of intraocular pressure (IOP). The long action is based on the melanin binding of the drugs that prolongs ocular drug retention and response. Overall, 63 new CAI-II compounds were synthesized and tested for melanin binding in vitro. Carbonic anhydrase affinity and IOP reduction of selected compounds were tested in rabbits. Prolonged reduction of IOP in pigmented rabbits was associated with increasing melanin binding of the compound. Installation of a single eye drop of a high melanin binder carbonic anhydrase inhibitor (CAI) resulted in ≈2 weeks' decrease of IOP, whereas the effect lasted less than 8 h in albino rabbits. Duration of the IOP response correlated with melanin binding of the compounds. Ocular pharmacokinetics of a high melanin binder compound was studied after eye drop instillation to the rat eyes. The CAI showed prolonged drug retention in the pigmented iris-ciliary body but was rapidly eliminated from the albino rat eyes. The melanin-bound drug depot maintained effective free concentrations of CAI in the ciliary body for several days after application of a single eye drop. In conclusion, melanin binding is a useful tool in the discovery of long-acting ocular drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland.
- Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5, 00014 Helsinki, Finland.
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland.
ORCID-Profile: Janika Jäntti, Arun Tonduru, Tapani Viitala, Arto Urtti
Förderung
- Research Council of Finland
- Business Finland
Zitieren
APA
Valtari, A., Kalinin, S., Jäntti, J., Vanhanen, P., Hanzlikova, M., Tonduru, A., Stenberg, K., Viitala, T., Vellonen, K. S., Toropainen, E., Ruponen, M., & Urtti, A. (2025). Melanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye. Molecular Pharmaceutics, 22(2), 721-732. https://doi.org/10.1021/acs.molpharmaceut.4c00694
Vancouver
Valtari A, Kalinin S, Jäntti J, Vanhanen P, Hanzlikova M, Tonduru A, et al. Melanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye. Molecular Pharmaceutics. 2025;22(2):721-732. doi:10.1021/acs.molpharmaceut.4c00694
BibTeX
@article{Valtari2025,
author = {Valtari, Annika and Kalinin, Stanislav and Jäntti, Janika and Vanhanen, Pekka and Hanzlikova, Martina and Tonduru, Arun and Stenberg, Katja and Viitala, Tapani and Vellonen, Kati-Sisko and Toropainen, Elisa and Ruponen, Marika and Urtti, Arto},
title = {Melanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {2},
pages = {721--732},
doi = {10.1021/acs.molpharmaceut.4c00694}
}
EUVIMED